Towards precision medicine in childhood leukemia - Insights from mutationally activated cytokine receptor pathways in acute lymphoblastic leukemia

Shai Izraeli; Chen Shochat; Noa Tal; Ifat Geron

doi:10.1016/j.canlet.2014.02.009

Towards precision medicine in childhood leukemia - Insights from mutationally activated cytokine receptor pathways in acute lymphoblastic leukemia

Shai Izraeli, Chen Shochat, Noa Tal, Ifat Geron

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

The successful therapy of childhood leukemia has been characterized by careful personalized adaptation of therapy by risk stratification. Yet almost all drugs are relatively non-specific. To achieve greater precision in therapy, druggable targets and specific targeting drugs are necessary. Here we review the recent discoveries of cytokine receptors and their signaling components in high risk leukemias and the potential approaches to target them.

Original language	English
Pages (from-to)	15-20
Number of pages	6
Journal	Cancer Letters
Volume	352
Issue number	1
DOIs	https://doi.org/10.1016/j.canlet.2014.02.009
State	Published - 28 Sep 2014
Externally published	Yes

Bibliographical note

Funding Information:
Our research on CRLF2 and IL7R is supported by the Israel Science Foundation legacy and iCORE programs (41/11), Israel Cancer Research Foundation, the William Lawrence & Blanche Hughes Foundation, Children With Cancer UK and the Swiss Bridge Foundation. S. Izraeli receives a research grant from Pfizer Inc. There is no conflict of interest.

Funding

Our research on CRLF2 and IL7R is supported by the Israel Science Foundation legacy and iCORE programs (41/11), Israel Cancer Research Foundation, the William Lawrence & Blanche Hughes Foundation, Children With Cancer UK and the Swiss Bridge Foundation. S. Izraeli receives a research grant from Pfizer Inc. There is no conflict of interest.

Funders	Funder number
Israel Cancer Research Foundation
Israel Science Foundation legacy	41/11
Pfizer
CHILDREN with CANCER UK
William Lawrence and Blanche Hughes Foundation
Swiss Bridge Foundation

Keywords

Acute lymphoblastic leukemia
CRLF2
Interleukin 7 receptor
Risk stratification

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.canlet.2014.02.009

Cite this

@article{e05ec9b413874e6abb84589e9f7049c4,

title = "Towards precision medicine in childhood leukemia - Insights from mutationally activated cytokine receptor pathways in acute lymphoblastic leukemia",

abstract = "The successful therapy of childhood leukemia has been characterized by careful personalized adaptation of therapy by risk stratification. Yet almost all drugs are relatively non-specific. To achieve greater precision in therapy, druggable targets and specific targeting drugs are necessary. Here we review the recent discoveries of cytokine receptors and their signaling components in high risk leukemias and the potential approaches to target them.",

keywords = "Acute lymphoblastic leukemia, CRLF2, Interleukin 7 receptor, Risk stratification",

author = "Shai Izraeli and Chen Shochat and Noa Tal and Ifat Geron",

note = "Funding Information: Our research on CRLF2 and IL7R is supported by the Israel Science Foundation legacy and iCORE programs (41/11), Israel Cancer Research Foundation, the William Lawrence & Blanche Hughes Foundation, Children With Cancer UK and the Swiss Bridge Foundation. S. Izraeli receives a research grant from Pfizer Inc. There is no conflict of interest. ",

year = "2014",

month = sep,

day = "28",

doi = "10.1016/j.canlet.2014.02.009",

language = "אנגלית",

volume = "352",

pages = "15--20",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Towards precision medicine in childhood leukemia - Insights from mutationally activated cytokine receptor pathways in acute lymphoblastic leukemia

AU - Izraeli, Shai

AU - Shochat, Chen

AU - Tal, Noa

AU - Geron, Ifat

N1 - Funding Information: Our research on CRLF2 and IL7R is supported by the Israel Science Foundation legacy and iCORE programs (41/11), Israel Cancer Research Foundation, the William Lawrence & Blanche Hughes Foundation, Children With Cancer UK and the Swiss Bridge Foundation. S. Izraeli receives a research grant from Pfizer Inc. There is no conflict of interest.

PY - 2014/9/28

Y1 - 2014/9/28

N2 - The successful therapy of childhood leukemia has been characterized by careful personalized adaptation of therapy by risk stratification. Yet almost all drugs are relatively non-specific. To achieve greater precision in therapy, druggable targets and specific targeting drugs are necessary. Here we review the recent discoveries of cytokine receptors and their signaling components in high risk leukemias and the potential approaches to target them.

AB - The successful therapy of childhood leukemia has been characterized by careful personalized adaptation of therapy by risk stratification. Yet almost all drugs are relatively non-specific. To achieve greater precision in therapy, druggable targets and specific targeting drugs are necessary. Here we review the recent discoveries of cytokine receptors and their signaling components in high risk leukemias and the potential approaches to target them.

KW - Acute lymphoblastic leukemia

KW - CRLF2

KW - Interleukin 7 receptor

KW - Risk stratification

UR - http://www.scopus.com/inward/record.url?scp=84906091502&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2014.02.009

DO - 10.1016/j.canlet.2014.02.009

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 24569093

AN - SCOPUS:84906091502

SN - 0304-3835

VL - 352

SP - 15

EP - 20

JO - Cancer Letters

JF - Cancer Letters

IS - 1

ER -

Towards precision medicine in childhood leukemia - Insights from mutationally activated cytokine receptor pathways in acute lymphoblastic leukemia

Abstract

Bibliographical note

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this